Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...
CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...
An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.
Thinking about CRISPR Therapeutics and wondering if now is your chance to scoop up value, or if the stock is already priced in with the excitement? Let's break down what the numbers and news say about ...
Scientists at St. Jude Children's Research Hospital and Northwestern University identified a previously unknown treatment ...
From revolutionary CRISPR treatment to heavy drinking dangers, here's what you need to know about the latest health research.
GLP-1s are being studied for a wide range of conditions. Now, scientists will test whether their anti-inflammatory properties ...
Sohini Ramachandran is a professor of biology, data science, and computer science at Brown University. C. Brandon Ogbunu is ...
ZME Science on MSN
Inside the Human Gene Editing Boom Driven by CRISPR Reshaping Everything From Medicine to Food
A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based ...
The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex ...
A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...
Pioneering CRISPR trial shows single infusion permanently lowers bad cholesterol by 50% in patients who don't respond to medication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback